UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Journal of clinical oncology, 2008-05, Vol.26 (15), p.2442-2448

2008

Volltextzugriff (PDF)

American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

Journal of clinical oncology, 2006-06, Vol.24 (18), p.2932-2947

2006

Volltextzugriff (PDF)

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4093-4098

2015

Volltextzugriff (PDF)

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

Journal of clinical oncology, 2011-04, Vol.29 (11), p.1495-1501

2011

Volltextzugriff (PDF)

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2822-2830

2005

Volltextzugriff (PDF)

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4112-4119

2003

Volltextzugriff (PDF)

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: Perception versus reality

Cancer, 2004-05, Vol.100 (10), p.2261-2268

2004

Volltextzugriff (PDF)

Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study

Supportive care in cancer, 2011-10, Vol.19 (10), p.1609-1617

2011

Volltextzugriff (PDF)

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art

Supportive care in cancer, 2011-03, Vol.19 (Suppl 1), p.43-47

2011

Volltextzugriff (PDF)

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

Supportive care in cancer, 2009-05, Vol.17 (5), p.589-594

2009

Volltextzugriff (PDF)

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

Journal of clinical oncology, 2009-11, Vol.27 (32), p.5363-5369

2009

Volltextzugriff (PDF)

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

The lancet oncology, 2009-06, Vol.10 (6), p.549-558

2009

Volltextzugriff (PDF)

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)

Supportive care in cancer, 2015-10, Vol.23 (10), p.2917-2923

2015

Volltextzugriff (PDF)

Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy

Cancer chemotherapy and pharmacology, 2014-10, Vol.74 (4), p.675-680

2014

Volltextzugriff (PDF)

Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kinetics

Journal of applied physiology (1985), 2013-04, Vol.114 (7), p.858-868

2013

Volltextzugriff (PDF)

Obstacles to the implementation of antiemetic guidelines

Journal of the National Comprehensive Cancer Network, 2009-05, Vol.7 (5), p.601-605

Grunberg, Steven M

2009

Volltextzugriff (PDF)

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update

Supportive care in cancer, 2005-02, Vol.13 (2), p.80-84

2005

Volltextzugriff (PDF)

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting

Cancer, 2003-05, Vol.97 (9), p.2290-2300

2003

Volltextzugriff (PDF)

Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives

Journal of the National Comprehensive Cancer Network, 2012-02, Vol.10 (2), p.149-157

2012

Volltextzugriff (PDF)

Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma

Cancer investigation, 2006-01, Vol.24 (8), p.727-733

2006

Volltextzugriff (PDF)

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

Cancer, 2005-10, Vol.104 (7), p.1548-1555

2005

Volltextzugriff (PDF)

Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement

Supportive care in cancer, 2011-03, Vol.19 (Suppl 1), p.1-4

2011

Volltextzugriff (PDF)

Supportive care during treatment for breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement

Breast (Edinburgh), 2013-10, Vol.22 (5), p.593-605

2013

Volltextzugriff (PDF)

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

The New England journal of medicine, 1999-01, Vol.340 (3), p.190-195

1999

Volltextzugriff (PDF)

Giving permission

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5477-5478

Grunberg, Steven M

2008

Volltextzugriff (PDF)

1 – 25 von 188

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(169)

Publikationsform

Artikel
(186)
Bücher
(1)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(132)
Life Sciences & Biomedicine
(130)
Humans
(125)
Oncology
(92)
Female
(68)
Medical Sciences
(67)
Biological And Medical Sciences
(66)
Male
(64)
Middle Aged
(57)
Chemotherapy
(50)
Vomiting - Chemically Induced
(47)
Vomiting - Prevention & Control
(45)
Antineoplastic Agents - Adverse Effects
(44)
Pharmacology. Drug Treatments
(44)
Aged
(43)
Adult
(42)
Antiemetics - Therapeutic Use
(42)
Nausea - Chemically Induced
(37)
Nausea - Prevention & Control
(34)
Neoplasms - Drug Therapy
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: Perception versus reality

Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)

Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy

Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kinetics

Obstacles to the implementation of antiemetic guidelines

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting

Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives

Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement

Supportive care during treatment for breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

Giving permission

Suchergebnisse filtern